LSTA
Lisata Therapeutics·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 1
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LSTA
Lisata Therapeutics, Inc.
A clinical-stage pharmaceutical company that developing innovative therapies for advanced solid tumors
Chemical and pharmaceutical
09/18/1980
08/05/2013
NASDAQ Stock Exchange
21
12-31
Common stock
P.O. Box 173, Liberty Corner, New Jersey 07938
Develops therapies for solid tumors.
Lisata Therapeutics, Inc., incorporated under the laws of the State of Delaware under the name of Fidelity Medical Services, Inc., was incorporated on September 18, 1980 and commenced operations in the current market in January 2006. The Company is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of solid tumors and other critical diseases. The company's lead research candidate, LSTA 1 (formerly CEND-1), is designed to activate a new uptake pathway that enables combined-administered or bundled anticancer drugs to penetrate solid tumors more effectively.
Company Financials
EPS
LSTA has released its 2026 Q1 earnings. EPS was reported at -0.5, versus the expected 0, missing expectations. The chart below visualizes how LSTA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
